Skip to content
Screener

GeneDx Holdings WGS Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$19.17M
Azenta logo
AzentaAZTA
$277.52M
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
NeoGenomics logo
NeoGenomicsNEO
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Labcorp Holdings logo
Labcorp HoldingsLH

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$2.3B-27.6%
Enterprise value$2.3B-27.0%
P/S5.2×-3.6×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001818331-26-000041
Line itemGross Carrying AmountAccumulated AmortizationAccumulated ImpairmentNet Carrying ValueWeighted-Average Amortization Period (Years)
Tradenames and trademarks$54,500$(12,514)$(4,225)$37,76112.1
Developed technology62,900(25,018)(10,182)27,7004.5
Customer relationships104,100(19,591)(5,001)79,50816.1
$221,500$(57,123)$(19,408)$144,96912.8

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is GeneDx Holdings's finite-lived intangible assets, accumulated amortization?
GeneDx Holdings (WGS) reported finite-lived intangible assets, accumulated amortization of $57.12M in Q1 2026.
How has GeneDx Holdings's finite-lived intangible assets, accumulated amortization changed year-over-year?
GeneDx Holdings's finite-lived intangible assets, accumulated amortization increased by 39.6% year-over-year, from $40.91M to $57.12M.

Ask your AI about GeneDx Holdings's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude